Cover Image
Market Research Report

Personalized Medicine Market: By Therapeutic Area (Cardiology, Antiviral, Others), By Application (Biomarker identification, Health Informatics, Others), By End-User (Hospitals, Research Laboratories, Others) & By Region-Forecast 2019-2024

Published by IndustryARC Product code 422332
Published Content info
Delivery time: 2-3 business days
Back to Top
Personalized Medicine Market: By Therapeutic Area (Cardiology, Antiviral, Others), By Application (Biomarker identification, Health Informatics, Others), By End-User (Hospitals, Research Laboratories, Others) & By Region-Forecast 2019-2024
Published: December 1, 2018 Content info:

Personalized medicine is drugs prepared based on the response produced by the patient suffering from a particular disease and carry certain biomarkers to cater the requirement of an individual patient. The key objective of personalized medicine is to recognize most appropriate treatment option for patient population. Globally, development of efficient and advance technology, higher prevalence of diseases, rise in the awareness among people regarding personalized medicine, increasing government initiative across the globe, growing development of genetic databases are the prime growth drivers of global personalized medicine market. In addition, increase in adoption of personalized medicine for cardio-renal, neurology, antiviral, pulmonary, psychiatry, and others, and emerging economies such as China, India and others, will create new opportunities for global personalized medicine market. However, higher cost of the research and development, and higher risk of side effects are the key restraints for global personalized medicine market.

Geographically North America dominated global personalized medicine market because of higher adoption of clinical practitioners, government funding, central integration of EHR and healthcare IT systems with hospital operations, high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, rise in consumer awareness, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the end-users, hospitals has the highest market share in global personalized medicine market.

This report identifies the global personalized medicine market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global personalized medicine market.

This report segments global personalized medicine market on the basis of therapeutic area, application, end-user, and regional market as follows:

Personalized Medicine Market, By Therapeutic Area: Cardiology, Antiviral, Psychiatry, Oncology, and Neurology

Personalized Medicine Market, By Application: Biomarker identification, Health Informatics, Companion Diagnostics, and Clinical Research

The report has focused study on personalized medicine market by basis of end-user such as: Hospitals, Research Laboratories, Academic Institutes, Bio and Health Informatics Companies, Service Providers, Partner, and Venture Capitalists

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the personalized medicine market. Some of the major companies' profiles in detail are as follows:

Siemens Healthcare Diagnostics Inc.

Laboratory Corporation of America

Becton Dickinson & Co.

Foundation Medicine Inc.

Bristol-Myers Squibb

Table of Contents

Table of Contents

1. Personalized Medicine Market - Market Overview

2. Executive Summary

3. Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Personalized Medicine Market- Market Forces

  • 4.1. Drivers
    • 4.1.1. Development of efficient and advance technology
    • 4.1.2. Higher prevalence of disease
  • 4.2. Restraints
    • 4.2.1. Higher cost of research and developments
  • 4.3. Opportunities
    • 4.3.1. Emerging economies
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Personalized Medicine Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Personalized Medicine Market, By Therapeutic Area

  • 6.1. Cardiology
  • 6.2. Antiviral
  • 6.3. Psychiatry
  • 6.4. Oncology
  • 6.5. Neurology

7. Personalized Medicine Market, By Application

  • 7.1. Biomarker identification
  • 7.2. Health Informatics
  • 7.3. Companion Diagnostics
  • 7.4. Clinical Research

8. Personalized Medicine Market, By End-User

  • 8.1. Hospitals
  • 8.2. Research Laboratories
  • 8.3. Academic Institutes
  • 8.4. Bio and Health Informatics Companies
  • 8.5. Service Providers
  • 8.6. Partner
  • 8.7. Venture Capitalists

9. Personalized Medicine Market, By Geography

  • 9.1. Europe
    • 9.1.1. Germany
    • 9.1.2. France
    • 9.1.3. Italy
    • 9.1.4. Spain
    • 9.1.5. Russia
    • 9.1.6. U.K.
    • 9.1.7. Rest of Europe
  • 9.2. Asia Pacific
    • 9.2.1. China
    • 9.2.2. India
    • 9.2.3. Japan
    • 9.2.4. South Korea
    • 9.2.5. Rest of Asia-Pacific
  • 9.3. North America
    • 9.3.1. U.S.
    • 9.3.2. Canada
    • 9.3.3. Mexico
  • 9.4. Rest of the World (RoW)
    • 9.4.1. Brazil
    • 9.4.2. Rest of RoW

10. Personalized Medicine - Market Entropy

  • 10.1. Expansion
  • 10.2. Technological Developments
  • 10.3. Merger & Acquisitions, and Joint Ventures
  • 10.4. Supply- Contract

11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

  • 11.1. Siemens Healthcare Diagnostics Inc.
  • 11.2. Laboratory Corporation of America
  • 11.3. Becton Dickinson & Co.
  • 11.4. Foundation Medicine Inc.
  • 11.5. Bristol-Myers Squibb
  • 11.6. 3G Biotech
  • 11.7. Quest Diagnostics
  • 11.8. Abbott
  • 11.9. Agendia NV
  • 11.10. Asuragen Inc

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

12. Appendix

  • 12.1. Abbreviations
  • 12.2. Sources
  • 12.3. Research Methodology
  • 12.4. Bibliography
  • 12.5. Compilation of Expert Insights
  • 12.6. Disclaimer
Back to Top